Cholinesterase inhibitor with anticholinergic agent
This page covers all Cholinesterase inhibitor with anticholinergic agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrolate), Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate), Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate/atropine).
Targets
Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrolate) · Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate) · Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate/atropine)
Marketed (2)
- neostigmine/glycopyrolate · Henry Ford Health System · Neurology / Anesthesia
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrolate blocks muscarinic receptors to counteract parasympathomimetic side effects. - Neostigmine and Glycopyrrolate · James J. Peters Veterans Affairs Medical Center · Neurology
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.
Phase 3 pipeline (2)
- neostigmine and glycopyrrolate or atropine · Merck Sharp & Dohme LLC · Neuromuscular disorders
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate or atropine blocks muscarinic receptors to prevent cholinergic side effects. - Combination of Neostigmine and Glycopyrrolate · James J. Peters Veterans Affairs Medical Center · Neuromuscular / Anesthesia
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract parasympathomimetic side effects.